Ariel DeMaio

Managing Editor

Ariel DeMaio is Managing Editor of Blood Cancers Today.

Articles by Ariel DeMaio

Ariel DeMaioAcute Lymphoblastic Leukemia | November 16, 2022
This article reviews the proposed mechanisms of action of venetoclax in AML and the potential future of venetoclax in AML.
Ariel DeMaioPrint | April 12, 2023
This phase II study enrolled 34 adult patients with intermediate- to high-risk myelofibrosis.
Ariel DeMaioAcute Lymphoblastic Leukemia | February 2, 2023
The chemotherapy-free approach of blinatumomab monotherapy could represent a promising therapy for older adults.
Ariel DeMaioAcute Lymphoblastic Leukemia | February 2, 2023
Drs. Short and Webster, discussed their differing views of the current position of transplantation in the treatment of ALL.
Ariel DeMaioChronic Lymphocytic Leukemia | February 1, 2023
Two adults who received infusions of anti-CD19 CAR T-cell therapy tisagenlecleucel were in remission at nine and ten years.
Ariel DeMaioPrint | November 29, 2022
Tisagenlecleucel was well-tolerated with manageable toxicity in patients with primary central nervous system lymphoma.
Ariel DeMaioMyeloma | November 14, 2022
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.
Ariel DeMaioT-Cell Lymphoma | November 14, 2022
Peripheral T-cell lymphomas represent about 10% to 15% of all non-Hodgkin lymphomas.
Ariel DeMaioAggressive B-Cell Lymphoma | February 1, 2023
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Ariel DeMaioChronic Lymphocytic Leukemia | February 2, 2023
Ibrutinib and venetoclax demonstrated superior MRD responses in older/unfit patients with previously untreated CLL.
Ariel DeMaioMyeloma | November 14, 2022
Patients with high-risk myeloma may not be appropriately recognized as having high-risk disease at diagnosis, according to a ...
Ariel DeMaioMyeloma | November 14, 2022
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the treatment ...